Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Unique flu vaccine trial to start in London

22.09.2006
Opportunity to trial new vaccine that could help in the fight against annual and pandemic flu

With winter on its way and the flu season about to begin Londoners are being offered the opportunity to sign up for a unique clinical trial to test a new DNA Vaccine. The trial, which has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA), will test for the first time whether a DNA vaccine can protect people from infection with influenza.

If successful, this challenge study could pave the way for DNA vaccines such as this H3 vaccine for annual flu and PowderMed’s H5N1 pandemic vaccine, to reach market approval. PowderMed also started a trial on the H5N1 DNA vaccine last month.

PowderMed’s Chief Medical Officer, Dr John Beadle said “This particular trial is unique because it will be the first to assess the ability of our DNA vaccine to protect human volunteers against flu. What we are looking for are people willing to be vaccinated and then later challenged with an annual flu virus. Some of them may get a mild form of influenza like illness, but our previous data suggests that those who are vaccinated may be protected. All volunteers will receive, at the end of the study, treatment with Tamiflu a licensed antiviral drug”.

... more about:
»DNA »Influenza »annual »trial

This trial is one of three being conducted this year by UK company PowderMed to assess the ability of DNA vaccines to protect against annual and pandemic influenza. PowderMed’s DNA vaccines use a proprietary needle-free system to deliver microscopic gold particles coated with DNA at supersonic speed into the immune cells of the skin. Previous studies have shown that these vaccines can protect animals from challenges with either annual or bird flu viruses and produce a protective level of immune response in humans.

The first phase of the trial is being conducted at Guys Drug Research Unit (GDRU), Quintiles UK Ltd in London. Dr Tim Mant, Senior Medical Advisor, GDRU said that “Annual flu is debilitating for many and life threatening for some; flu is a major public health issue and we feel it is important to contribute to knowledge about potential new vaccines. We are currently screening volunteers to determine whether they may be eligible to enroll in this influenza vaccine study.”

Later in the trial the volunteers will be accommodated for ten days in a residential facility, where they will be challenged with an enfeebled version of the H3N2 strain of influenza virus which is known to cause annual influenza in non-immunised people. At the end of this period the volunteers will all be given Tamiflu, an antiviral drug, already approved for use in the UK to reduce the duration of any potential influenza symptoms.

Full details of this clinical study and directions for potential volunteers can be found at www.clinicaltrials.gov. Anyone interested, who is otherwise healthy and aged between 18 and 50, should contact Quintiles at Guys Drugs Research Unit on 0800 634 1130.

Christelle Kerouedan | alfa
Further information:
http://www.powdermed.com

Further reports about: DNA Influenza annual trial

More articles from Life Sciences:

nachricht Symbiotic bacteria: from hitchhiker to beetle bodyguard
28.04.2017 | Johannes Gutenberg-Universität Mainz

nachricht Nose2Brain – Better Therapy for Multiple Sclerosis
28.04.2017 | Fraunhofer-Institut für Grenzflächen- und Bioverfahrenstechnik IGB

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Fighting drug resistant tuberculosis – InfectoGnostics meets MYCO-NET² partners in Peru

28.04.2017 | Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

 
Latest News

Wireless power can drive tiny electronic devices in the GI tract

28.04.2017 | Medical Engineering

Ice cave in Transylvania yields window into region's past

28.04.2017 | Earth Sciences

Nose2Brain – Better Therapy for Multiple Sclerosis

28.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>